Core Viewpoint - Aidi Kang Holdings (09860) has seen a significant stock price increase of 7.59%, reaching HKD 7.51, following the announcement of a strategic acquisition of Crown Bioscience International for USD 204 million, which aligns with the company's growth strategy in expanding its product portfolio [1][1][1] Group 1: Acquisition Details - Aidi Kang Holdings announced a share purchase agreement with Miramar Lifesciences Limited and JSR Life Sciences, LLC to acquire 100% of Crown Bioscience International [1] - The acquisition is valued at USD 204 million and is expected to be completed after the trading period on November 13, 2025 [1][1] - Following the completion of the acquisition, Crown Bioscience will become a wholly-owned subsidiary of Aidi Kang Holdings [1] Group 2: Strategic Implications - The target company, Crown Bioscience, is a global Contract Research Organization (CRO) focused on advancing precision medicine in oncology, immuno-oncology, and other therapeutic areas [1] - Crown Bioscience collaborates with biotech and pharmaceutical companies to accelerate drug development through integrated preclinical, translational, and clinical biomarker services [1] - The board of Aidi Kang Holdings believes that this acquisition aligns with the group's development strategy to expand its product offerings and will provide long-term strategic benefits [1][1]
港股异动 | 艾迪康控股(09860)高开逾7% 拟2.04亿美元收购冠科生物全部股权